The 2023 MedTech Forum attracted record interest from industry delegates in Europe and beyond. Two days of public sessions included the popular “CEOs No Filter” roundtables, where senior sector representatives were given carte blanche to appraise the state of Europe’s industry.
MedTech Europe’s 2023 MedTech Forum was held in Dublin, Ireland, under new chief executive Oliver Bisazza, the association’s former director of regulatory affairs. He had big shoes to fill, leading his first annual MTF after long-standing incumbent Serge Bernasconi announced his planned retirement on stage at the 2022 event in Barcelona, Spain.
Opening MTF 2023 proceedings on 31 May, Bisazza said over a thousand delegates had registered, the largest number since the...
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
Digital clinical trials, a trend sparked by the COVID-19 pandemic that has held the biopharma industry’s interest, are changing the way patients interact with research and improving access, says Medable’s CEO.
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Introducing the all-new Citeline News and Insights app, providing seamless access to all your favorite award-winning publications. Explore the latest articles from Pink Sheet, Scrip, In Vivo, Medtech Insight, Generics Bulletin and HBW Insight, all in one stylish, intuitive and user-friendly platform.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
